REG - LungLife AI, INC - Posting of Circular and Notice of Special Meeting

LungLife AIAnnouncement

06/03/2024 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240306:nRSF8933Fa&default-theme=true

RNS Number : 8933F  LungLife AI, INC  06 March 2024

 

6 March 2024

LungLife AI Inc

(the "Company" or "LungLife")

 

Posting of Circular

And Notice of Special Meeting

 

LungLife AI Inc (AIM: LLAI), a developer of clinical diagnostic solutions for
the early detection of lung cancer, confirms that further to the announcements
on 4 and 5 March 2024, a Circular in connection with the Placing and
Subscription (the "Circular"), including the Notice of Special Meeting, has
today been despatched to shareholders. A copy of the Circular and Notice of
Special Meeting is available on the Company's website at
https://lunglifeai.com/investors/shareholder-information/
(https://urldefense.proofpoint.com/v2/url?u=https-3A__lunglifeai.com_investors_shareholder-2Dinformation_&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=RXEgD2sy17iU21u6z4qOYU9uK8WGQ51N8K4QC3EH2Vk&m=PQ9QMGo8gb09SUpvhX6xdMQ6xvudwSnRxYb-EpLuwgS2A5yaylfs7kiPsknvPkS3&s=fTD2zkBlI31aQsxSRT82DKyuskgw3pGIry2sFVRk2qU&e=)
.

 

The Special Meeting will be held at 11.00 a.m. on 21 March 2024 at Mayer Brown
International LLP, at 201 Bishopsgate, London, EC2M 3AF and online by virtual
link.

 

The Form of Proxy for use in connection with the Special Meeting should be
completed and returned in accordance with the instructions thereon so as to be
received by the Company's registrars, Link Group, PXS1, Central Square, 29
Wellington Street, Leeds, LS1 4DL by no later than 11.00 a.m. on 19 March
2024.

 

The Form of Direction for use in connection with the Special Meeting should be
completed and returned in accordance with the instructions thereon so as to be
received by the Company's registrars, Link Group, PXS1, Central Square, 29
Wellington Street, Leeds, LS1 4DL by no later than 11.00 a.m. on 18 March
2024.

 

Completion of the Form of Proxy or Form of Direction will not preclude
shareholders from attending and voting in person at the Special Meeting should
the so wish.

 

The Board believe that each of the Resolutions is in the best interest of the
Company and its shareholders as a whole and unanimously recommends
shareholders to vote in favour of them, as the Directors have irrevocably
undertaken to do in respect of their own beneficial shareholdings, which in
aggregate represent 0.17 per cent. of the Common Shares currently in issue.

 

Unless otherwise defined herein, capitalised terms used in this announcement
shall have the same meanings as defined in the announcement released by the
Company on 4 March 2024.

 

For further information please contact:

 

 LungLife AI, Inc.                                         www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                          Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Joint Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Cameron MacRitchie / Lydia Zychowska

 Goodbody Stockbrokers UC (Joint Broker)                   Tel: +44 (0)20 3841 6202

 Tom Nicholson / Cameron Duncan / William Hall

 Walbrook PR Limited                                        Tel: +44 (0)20 7933 8780
 Paul McManus / Alice Woodings / Phillip Marriage          or LungLifeAI@walbrookpr.com (mailto:LungLifeAI@walbrookpr.com)

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGBRGDXDXGDGSL